Experience of application of a new generation coronary stents--biodegradable stent--platforms--was summarized, in 46 patients, suffering an ischemic heart disease, 60 stents "Absorb" were implanted. Unstable course of the disease was noted in 6 (13.0%) patients, coronary angina of functional class II--III--in 40 (87%). Early stenting was accomplished in 10, aortocoronary shunting--in 4 patients, and abdominal aorta endoprosthesis--in 1. One stent "Absorb" was implanted to 33 patients, two stents--to 11, four biodegradable stents--1. In one observation the stenting of coronary arteries and a. carotis interna was conducted. In all the patients the immediate postoperative period course was uneventful, unfaithful implantation or an acute thrombosis of stent were not observed. The investigation results witnesses the possibility of application of this technology in various clinical and angiographic situations. For wide introduction of biodegradable stents into practice of interventional cardiology departments it is necessary to proceed with the immediate and late follow-up results studying.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.
Development of self-gelling powder combining chitosan/ bentonite nanoclay/ sodium polyacrylate for rapid hemostasis: In vitro and in vivo study.
Int J Biol Macromol
December 2024
Institute of Tissue Regeneration, Soonchunhyang University, Cheonan 31151, Republic of Korea; Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea. Electronic address:
Although hemostatic powders are commonly used in clinical and emergency settings, they frequently show poor absorption, raise cytotoxicity issues, and are not effective for fatal non-compressible bleeding. The purpose of this research is to create a self-gelling hemostatic powder based on chitosan, bentonite, and sodium polyacrylate (CBS) to improve the hemostatic effect. When liquid comes into contact with CBS powders, they can fuse and form a stable hydrogel in less than 30s.
View Article and Find Full Text PDFIntracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy.
Mol Pharm
January 2025
Industrial Pharmacy, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of the tumor is almost always guaranteed due to the infiltrative nature of the disease. Moreover, the blood brain barrier imparts an additional layer of complexity by impeding the delivery of therapeutic agents to the tumor, hence limiting the efficacy of systemically delivered drugs.
View Article and Find Full Text PDFFive-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT.
Cardiovasc Revasc Med
November 2024
U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy. Electronic address:
Background: Data on Absorb bioresorbable vascular scaffold (BVS) use in patients presenting with ST-segment elevation myocardial infarction (STEMI) are limited. Furthermore, Absorb studies including STEMI patients lacked a prespecified implantation technique to optimize BVS deployment. This study examines the 5-year outcomes of BVS in STEMI patients using an optimized implantation strategy and the impact of prolonged dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFBioresorbable Scaffolds for Below-the-Knee Arterial Disease: A Literature Review of New Developments.
Rev Cardiovasc Med
April 2024
Department of Vascular Surgery, Luhe Hospital Affiliated to Capital Medical University, 101199 Beijing, China.
This review aimed to explore the therapeutic effect of bioabsorbable stents in the inferior genicular artery, from the emergence of absorbable bare metal stents to the latest technology in polymer and anti-proliferative eluting drugs mixed with coated bioresorbable vascular stents (BVSs). Currently, there are conflicting data regarding the safety and effectiveness of BVSs in infrapopliteal artery interventions, especially compared to the current generation of drug-eluting stents (DESs). This review will cover the existing data on BVSs in reconstructing the infrapopliteal arterial blood flow and active clinical trials for future iterations of BVSs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!